Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis

Ylermi Soini1, Tuula Salo, Jari Satta

  • 1Department of Pathology, University of Oulu and Oulu Hospital, Oulu, Finland.

Human Pathology
|September 25, 2003
PubMed

Insights

Angiogenesis, the formation of new blood vessels, is present in aortic valve stenosis and linked to inflammation. Statin therapy may reduce this vascularization in affected patients.

Area of Science:

  • Cardiovascular Biology
  • Pathology
  • Molecular Medicine

Background:

  • Angiogenesis is crucial for embryogenesis and disease progression, including cancer and inflammation.
  • Its role in cardiovascular pathologies like atherosclerosis is established, but its impact on aortic stenosis remains debated.
  • Excessive vascularization may contribute to cardiovascular issues, necessitating further investigation into aortic valve stenosis.

Purpose of the Study:

  • To investigate the role of angiogenesis in nonrheumatic aortic valve stenosis.
  • To assess vascular density and expression of angiogenic factors (VEGF) and their receptors (Flt-1, Flk-1) in aortic valves.
  • To examine the correlation between angiogenesis, inflammation, and statin therapy in aortic stenosis.

Main Methods:

  • Immunohistochemistry was used to evaluate vascular density (FVIII), VEGF, VEGF receptors (Flt-1, Flk-1), and nitric oxide synthase (eNOS, iNOS, nNOS) in 55 diseased and 6 control aortic valves.
  • Immunoblotting verified immunohistochemical findings for VEGF and its receptors.
  • Statistical analysis correlated vascular density with inflammation markers and statin use.

Main Results:

  • Vascular density was significantly higher in diseased aortic valves, particularly with moderate stenosis and chronic inflammation (P = 0.007).
  • Patients on statin therapy exhibited significantly lower vascular densities (P = 0.001).
  • Enhanced vascular density correlated with increased expression of Flk-1 and endothelial eNOS (P < 0.05), and showed a tendency with VEGF.

Conclusions:

  • Nonrheumatic aortic valve stenosis demonstrates a distinct angiogenic response with the presence of key angiogenic factors.
  • Angiogenesis, particularly driven by VEGF and nitric oxide pathways, may play a significant role in the development of aortic valve stenosis.
  • Findings suggest potential therapeutic targets for managing aortic valve stenosis by modulating angiogenesis.

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...